Microbiology

2026 articles:

Poliovirus: The Paralytic Pathogen We Shouldn’t Forget

By Priya Dhagat

This article originally appeared in the May-June 2026 issue of Healthcare Hygiene magazine.

April 26–30, 2026 marks World Immunization Week—a time to promote the lifesaving power of vaccines, raise public awareness, and strengthen trust in public health systems. Yet outbreaks of measles, pertussis, and other preventable diseases have become increasingly common, driven by declining vaccination rates, misinformation, and funding shortfalls. Amid these alarming trends, one vaccine-preventable virus demands continued vigilance: poliovirus—a highly contagious pathogen capable of causing irreversible paralysis.

With the overwhelming new headlines these vaccine-preventable disease outbreaks, let’s not forget about this debilitating, paralytic, and contagious virus.

From ancient Egyptian paintings depicting limb paralysis to photos of children in iron lungs in the 1950s, polio was historically one of the most feared diseases and a major global health crisis in the early 20th century. In 1952, the U.S. recorded over 58,000 cases of polio making it the largest reported outbreak in U.S. history.

Poliovirus is a small, nonenveloped, single-stranded RNA virus in the Enterovirus genus of the Picornaviridae family. It has a highly stable capsid that is resistant to environmental degradation, which enables the virus to persist in water or food for weeks. The capsid is resistant to certain detergents, alcohol, and mild temperatures, but susceptible to higher temperatures, UV light, and bleach. Humans are the only known reservoir for poliovirus.

Poliovirus primarily targets and infects microfold (M) cells—specialized epithelial cells located within the mucosal tissues of the intestine, lungs, and nasopharynx. Because these cells have relatively low levels of protective mucosal IgA, they serve as key entry points for the virus. Following entry into intestinal M cells and initial replication, the virus may continue to spread to local lymphoid tissues and, in some cases, enter the bloodstream. From there, the virus may reach the central nervous system where it selectively infects and destroys motor neurons in the spinal cord and brainstem leading to paralysis. Poliovirus also binds to bacterial surface polysaccharides of the gut microbiome, allowing for additional stability and leading to prolonged viral shedding in feces which facilitates its fecal-oral transmission route.

Most poliovirus infections in children are either asymptomatic or cause only a mild illness. However, in approximately 0.1–1% of cases, the virus progresses to paralytic poliomyelitis, a severe and potentially life-altering condition. The incubation period typically ranges from 3 to 6 days for nonparalytic illness and extends to about 7 to 21 days in cases that develop paralysis.

There are two types of polio vaccines: inactivated polio vaccine and oral polio vaccine. In 1955, Dr. Jonas Salk developed the first polio vaccine which contained inactivated poliovirus strains, stimulating the production of antibodies in the bloodstream. In 1961, Dr. Albert Sabin developed an oral vaccine (OPV) which contained weakened live poliovirus strains, providing immunity in the intestines. A major consequence of OPV was the emergence of vaccine-derived polioviruses in which poliovirus strains in the OPV mutate and could circulate in under-vaccinated communities causing vaccine-associated paralytic polio. The oral polio vaccine is no longer licensed or available in the USA. Polio continues to be endemic in Afghanistan and Pakistan. Several African countries have reported vaccine-derived poliomyelitis due to poor sanitation coverage and low routine immunization uptake. Sporadic cases can still occur, even in the United States. In 2022, an unvaccinated adult in New York developed acute flaccid myelitis caused by a poliovirus genetically linked to a vaccine-derived type 2 strain. This was the first U.S. case in nearly a decade and prompted an intensive public health response, including mass vaccination efforts and wastewater surveillance. The incident served as a stark reminder of the serious outcomes of this devastating, but vaccine-preventable, infectious disease.

Priya Dhagat is an infection preventionist (at Bellevue Hospital in New York, N.Y.

 

References:

Polio's Last Stand: The Global Fight for Eradication

Poliomyelitis: Historical Facts, Epidemiology, and Current Challenges in Eradication - PMC

https://www.who.int/news-room/spotlight/history-of-vaccination/history-of-polio-vaccination

https://pubmed.ncbi.nlm.nih.gov/2152776/#:~:text=Abstract,of%20the%20intestinal%20epithelial%20barrier.

https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-18-poliomyelitis.html#:~:text=During%20intestinal%20replication%2C%20the%20virus,cells%20results%20in%20distinctive%20paralysis.

https://www.cell.com/structure/fulltext/S0969-2126(96)00084-6#:~:text=Poliomyelitis%20is%20caused%20by%20poliovirus%2C%20a%20typical,a%20single%20strand%20of%20messenger%20sense%20RNA.

https://polioeradication.org/circulating-vaccine-derived-poliovirus-count/

https://www.cdc.gov/mmwr/volumes/71/wr/mm7133e2.htm

 

 

Will Physicians and Medical Laboratory Professionals Be Prepared to Diagnose the Return of Vaccine-Preventable Infections?

By Rodney Rohde, PhD, MS, SM(ASCP) CM, SVCM, MBCM, FACSc

This article originally appeared in the March-April 2026 issue of Healthcare Hygiene magazine.

The recent resurgence of vaccine-preventable infections like measles, pertussis, mumps, and even threats of polio returning to pockets of the United States raises a critical question: Are we ready to diagnose these diseases when they reappear? This isn’t a theoretical exercise. The world has witnessed measles outbreaks after years of elimination, pertussis clusters despite vaccine availability, and environmental detections of poliovirus in wastewater. These trends are a stark reminder that pathogens once considered “under control” can re-emerge when immunization coverage falters, global travel persists, and diagnostic readiness lags.

At the heart of preparedness are two interconnected groups of professionals – physicians, who are the clinical front line, and medical laboratory professionals, who perform the essential work of identifying and confirming infections. Both communities must be equipped with the knowledge, tools, and systems necessary to recognize and respond swiftly when these diseases return.

A Changing Clinical Landscape

For decades, many clinicians in the United States rarely saw cases of measles or polio. Generation after generation of physicians trained and practiced in settings where these diseases were “out of sight.” But absence of disease does not equal absence of risk. The risk has increased as vaccine hesitancy, misinformation, and gaps in immunization coverage have undermined herd immunity—the community shield that protects vulnerable people and keeps outbreaks limited.

Today’s physician must have a renewed awareness that classic pediatric infectious diseases are not relics of the past. Cough with paroxysms and post-tussive vomiting should trigger thoughts of pertussis. A febrile rash with Koplik spots in a traveler should raise alarm bells for measles. Acute onset of high fevers and severe muscle stiffness in an unimmunized child could signify polio or other enterovirus infection.

Diagnosis begins with clinical suspicion—and that requires training, visibility, and experience. Medical schools and residency programs must reinvigorate infectious disease curricula with content that bridges historical knowledge with modern practice. Continuing medical education (CME) programs should emphasize recognition of vaccine-preventable diseases (VPDs) in both typical and atypical presentations.

Diagnostic Laboratories: Tools, Training, and Turnaround

Physicians rely on laboratory confirmation to confidently diagnose VPDs. Yet diagnostic readiness in laboratories varies across the country. Laboratories must maintain capacity for testing that goes beyond routine panels. Too many labs have eliminated specialized assays, particularly for rare diseases, because of financial and workflow pressures. This limits local ability to rapidly detect cases and creates dependence on public health or reference laboratories—with added days of delay.

To address this gap, laboratories must invest in capable molecular platforms, maintain reagents for targeted PCRs, and ensure staff are trained to run and interpret specialized assays. Quality assurance programs should include proficiency testing for VPDs and regular competency assessments.

Moreover, laboratory professionals must understand when to escalate testing – especially for notifiable diseases. For example, a respiratory panel that detects Bordetella pertussis requires prompt public health notification. A suspected measles case mandates immediate serology and PCR, coordinated swiftly with public health partners.

Public Health Integration: Diagnosis Is More Than a Result

Preparedness isn’t just about detection; it’s about integration with public health systems. Rapid reporting of confirmed or suspected VPDs enables contact tracing, outbreak mitigation, and immunization campaigns. The laboratory diagnosis becomes actionable only when it triggers public health response.

Physicians and laboratory professionals need clear understanding of reporting requirements and established communication channels. Electronic health records should be configured for prompt alerts to health departments. Laboratories should have protocols for immediate notification of results that signal public health risk.

Diagnostic Stewardship and Recognition Bias

In a clinical era dominated by broad syndromic panels and rapid multiplex tests, there is a risk of diagnostic complacency. If measles or mumps isn’t included in a standard panel, clinicians may overlook targeted testing. Diagnostic stewardship—the practice of thoughtfully choosing which tests to order based on clinical judgment—must evolve to include VPDs in differential diagnoses, especially in high-risk contexts like travel, low-immunization communities, or daycare exposures.

This requires collaboration: physicians must communicate clinical suspicion clearly to laboratories, and laboratory professionals must be willing to engage, ask questions, and recommend additional testing when appropriate.

Education, Simulation, and Preparedness Exercises

Real readiness comes from practice. Healthcare systems should integrate simulation exercises that include identification of VPDs. These drills can test the entire chain—from patient presentation and clinician evaluation, through specimen collection and laboratory testing, to public health notification and outbreak control.

Medical laboratory educational programs should include modules on VPDs, outbreak detection, and biosafety protocols. Workshops and case reviews strengthen skills and ensure that both new and experienced professionals are comfortable with rare but high-impact diagnoses.

Addressing Misinformation and Reinforcing Vaccination

Ultimately, preparedness also includes prevention. Laboratory and clinical professionals often serve as trusted voices in their communities. When physicians explain why vaccines protect not just individuals but entire communities, and when laboratorians articulate why detection matters, they help counter misinformation.

Effective diagnosis doesn’t occur in a vacuum—it occurs in societies where understanding and trust are vital.

Conclusion: The Time Is Now

The resurgence of vaccine-preventable infections is not a distant possibility—it is happening now. Measles, pertussis, mumps, and the specter of polio remind us that infectious diseases evolve, populations change, and immunity is never static.

Physicians and laboratory professionals are central to our collective defense. Preparedness means sharpening clinical acumen, maintaining robust diagnostic capacity, reinforcing public health partnerships, and embracing education at every level.

The question isn’t whether these diseases will return – it’s whether we will be ready when they do. The answer depends on the choices we make today: in training, investment, communication, and commitment to vaccination and diagnosis. Under the microscope, preparedness is not just a goal – it is an imperative.

 

Rethinking Vaccination Policy and Reinforcing Public Health’s Foundation

By Rodney Rohde, PhD, MS, SM(ASCP) CM, SVCM, MBCM, FACSc

This article originally appeared in the Jan-Feb 2026 issue of Healthcare Hygiene magazine.

Recent decisions to overhaul the U.S. childhood immunization schedule represent one of the most consequential shifts in public health policy in generations. As public health professionals, clinicians, and educators, we must examine not only the clinical implications of these changes, but also their broader impact on public health infrastructure, trust in science, and our ability to prevent disease. The conversation ahead is not simply about vaccines—but about the role of evidence, expertise, and infrastructure in protecting community health.

  1. What the New Childhood Vaccination Recommendations Mean for Public Health

On Jan. 5, 2026, the Centers for Disease Control and Prevention (CDC), acting under a presidential memorandum, announced a sweeping revision of the U.S. childhood immunization schedule. The revised guidance reduces the set of vaccines universally recommended for all children from coverage of approximately 17 diseases to a narrower list focused on about 11 diseases, such as measles, mumps, rubella, polio, and a one-dose human papillomavirus (HPV) recommendation. Other vaccines—such as those for influenza, COVID-19, rotavirus, hepatitis A and B, meningococcal disease, and RSV—have been shifted to a “shared clinical decision-making” model or targeted at high-risk groups instead of a blanket recommendation for all children.

Proponents of the change argue that aligning the U.S. schedule with peer nations can restore public confidence and reduce what they describe as “over-vaccination,” noting that many developed countries recommend fewer routine vaccines yet achieve strong outcomes. They frame the shift as empowering parents and clinicians to make individualized decisions.

However, with such dramatic policy shifts come profound consequences:
Most importantly, trust in public health—already eroded in recent years—risks further decline. Between 2020 and 2024, public confidence in healthcare institutions significantly waned, in part due to pandemic response tensions and polarization—an issue that played a role in prompting this revision.

International comparisons can be misleading. Nations with fewer recommended vaccines often simultaneously maintain universal healthcare, robust public health systems, and high baseline vaccination coverage. The U.S. health ecosystem—including fragmented access, variable insurance coverage, and unequal health literacy—differs in fundamental ways from many European and Asian systems. Policy developers must recognize these core differences when contemplating changes that hinge on cross-national comparisons.

Lowering the bar on what constitutes a universal vaccine recommendation may unintentionally signal that certain preventable diseases are less serious or require less protection. This messaging can exacerbate vaccine hesitancy in an era where misinformation already undermines uptake. Institutions like the Pediatric Infectious Diseases Society (PIDS) have warned that confusing guidance could reduce coverage and increase outbreaks of preventable diseases; such warnings must be taken seriously by health leaders.

  1. The Broader Public Health Picture: Infrastructure, Experts & Education

A robust vaccination schedule is deeply intertwined with the strength of our public health system at every level: federal, state, local, and community. Vaccination programs do not operate in isolation—their success depends on a reliable workforce, trusted communicators, accessible infrastructure, surveillance systems, and public education.

Public health infrastructure is the bedrock of disease prevention and health promotion in communities. It encompasses not only physical systems like laboratories and electronic surveillance, but also workforce capacity, data systems, policy frameworks, and community partnerships. Healthy People 2030 identifies public health infrastructure as essential to delivering foundational health services, including vaccinations, chronic disease prevention, emergency preparedness, and health monitoring.

Yet structural weaknesses persist. Decades of underfunding have restricted the ability of health departments to recruit, train, and retain skilled professionals, maintain up-to-date laboratories, and leverage data for rapid response. Reports have highlighted workforce shortages, difficulty filling specialized roles such as epidemiologists and informatics specialists, and significant turnover in public health staffing—challenges that weaken preparedness and response.

Supporting expert public health personnel is not a luxury—it is a strategic imperative. Highly trained epidemiologists, infection preventionists, laboratory scientists, and health communicators form the backbone of our ability to detect outbreaks early, evaluate vaccine safety and effectiveness, and educate the public in culturally sensitive ways. This expertise cannot be substituted by rhetoric or ad hoc decision-making. Federal and state initiatives must prioritize hiring incentives, retention strategies, advanced training, and continuing education to create a resilient workforce.

Education—both for professionals and the public—is equally critical. Health literacy equips individuals to understand risks, benefits, and the scientific foundations of preventive care. Continuous professional education ensures that clinicians and health department staff stay abreast of evolving evidence, new technologies, and emerging pathogens. Schools of public health, professional associations, and academic partnerships play a vital role in ensuring the next generation of public health leaders is equipped with the skills needed for 21st-century challenges.

A Call to Action for Health Professionals and Policy Makers

To mitigate the potential negative impacts of the new vaccination framework and strengthen the broader public health system, we must pursue the following:

  1. Advocate for evidence-based policy. Public health decisions should be grounded in transparent, peer‐reviewed science, with clear communication of the rationale, benefits, and limitations. Public trust depends on clarity and consistency.
  2. Invest in infrastructure and workforce development. Adequate funding, workforce pipelines, competitive compensation, and support for local health departments are non-negotiable if we are to sustain disease prevention and rapid response capabilities.
  3. Expand public education and engagement. Combating misinformation and increasing health literacy must be central to public health strategy. Communities should understand not only what the recommendations are, but why they matter.
  4. Strengthen partnerships across sectors. Collaboration with clinical medicine, academia, community organizations, and media can amplify accurate information and integrate public health perspectives into broader societal decision-making.

The path forward requires courage, collaboration, and commitment to the principles of science and equity. Vaccination schedules, infrastructure investment, and educational outreach are not isolated tasks—they are components of a comprehensive strategy to protect children, communities, and our collective future. As healthcare and public health professionals, we must continue to champion these foundations with integrity, expertise, and a deep commitment to public wellbeing.

Rodney E. Rohde, PhD, MS, SM(ASCP) CM, SVCM,MBCM, FACSc, is the Regents’ Professor, Texas State University System; University Distinguished Chair & Professor, Clinical Laboratory Science (CLS); TEDx Speaker & Global Fellow – Global Citizenship Alliance; Texas State Honorary Professor of International Studies; Associate Director, Translational Health Research Initiative; Past President, Texas Association for CLS.